Haemonetics Corporation HAE
NYSE
| 09/26/2026 | 06/27/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 5.42% | -2.01% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.42% | -2.01% | |||
| Cost of Revenue | 0.94% | -8.31% | |||
| Gross Profit | 8.40% | 2.69% | |||
| SG&A Expenses | -0.43% | -7.16% | |||
| Depreciation & Amortization | 1.95% | -2.74% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.64% | -6.62% | |||
| Operating Income | 27.26% | 26.61% | |||
| Income Before Tax | 32.13% | 267.52% | |||
| Income Tax Expenses | 13.66% | 276.49% | |||
| Earnings from Continuing Operations | 40.28% | 263.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 40.28% | 263.85% | |||
| EBIT | 27.26% | 26.61% | |||
| EBITDA | 19.59% | 26.96% | |||
| EPS Basic | 39.85% | 266.94% | |||
| Normalized Basic EPS | 27.50% | 37.44% | |||
| EPS Diluted | 38.89% | 264.87% | |||
| Normalized Diluted EPS | 25.80% | 36.40% | |||
| Average Basic Shares Outstanding | 0.31% | -1.87% | |||
| Average Diluted Shares Outstanding | 1.66% | -1.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||